Updates are available Correction dated 2025-07-12
Click to view Correction: https://doi.org/10.1007/s12325-025-03235-2
-
Authors
Lebwohl, Mark G.
Koo, John Y.
Jaworski, Janusz
Trefler, Jakub https://orcid.org/0009-0003-3912-3518
Daniluk, Stefan
Dudek, Anna
Baran, Wojciech
Owczarek, Witold
Kolinek, Joanna
Brzewski, Paweł
Sikora, Mariusz
Krogulec, Marek
Kim, SungHyun https://orcid.org/0000-0003-3898-0393
Bae, YunJu https://orcid.org/0009-0002-3827-6742
Jeon, DaBee
Choi, EunJin
Cha, JungBin
Lee, HyunJin
Choi, SuJin
Pariser, David M.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05495568 at ClinicalTrials.govDocuments that mention this clinical trial
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study
https://doi.org/10.1007/s12325-024-03100-8
-
Funding
Funding for this research was provided by:
Celltrion
- License Information
-
More Information
Article History
Received: 21 November 2024
Accepted: 18 December 2024
First Online: 11 February 2025
Change Date: 12 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-025-03235-2
Declarations
:
: Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, EPI, Evommune Inc., Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. John Y. Koo is a consultant for Arcutis and Castle Pharmaceutical Corporation and is a speaker for AbbVie, Amgen, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Leo, Ortho-Dermatologic, Pfizer, Sanofi-Regeneron, and UCB. Paweł Brzewski has received consulting fees from AbbVie, Aristo, Eli Lilly, and Leo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, and/or educational events from Eli Lilly, Leo, and Pfizer; payment for expert testimony from Avene, Cutis Lab, and La Roche Posay; support for attending meetings and/or travel from AbbVie, Leo, and UCB; has patents planned, issued, or pending from Leo; and is a member of EADV and a secretary for PDV Krakow. Marek Krogulec has received support for attending meetings and/or travel from Accord, Adamed, Belin-Chemie, Egis, Medac, and Sandoz. SungHyun Kim is an employee of Celltrion. YunJu Bae, DaBee Jeon, EunJin Choi, JungBin Cha, HyunJin Lee, and SuJin Choi are employees and stockholders of Celltrion, Inc. David M. Pariser has received consulting fees from Celltrion and has participated on a Data Safety Monitoring Board and/or Advisory Board for Celltrion. Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Anna Dudek, Wojciech Baran, Witold Owczarek, Joanna Kolinek, and Mariusz Sikora have nothing to declare.
: All patients provided written, informed consent. The study was conducted in line with the principles of the Declaration of Helsinki 1964 (and its later amendments) and of Good Clinical Practice. Study protocols and documentation were approved by local independent ethics committees or institutional review boards at each study center (Table ).
